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• Lack of motivation for planning, organising and attention (Executive apathy) 
and self generation of thought or behaviour (Initiation apathy) were observed 
in PD  
• Apathy subtype deficits were found to be related to impairment of activities of 
daily living in PD 
• The Dimensional Apathy Scale (DAS) is a valid and reliable multidimensional 
apathy measure in PD 
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Objective: Apathy is a prominent and disabling symptom in PD and is a 
multidimensional behaviour, but which dimensions are specifically affected is 
unclear. Therefore the aim of this preliminary study was to determine the 
psychometric properties of the Dimensional Apathy Scale (DAS) and explore the 
multidimensional profile of apathy in PD patients. Methods: 34 PD patients, with 30 
of their informants/carers, and 34 healthy controls with, 30 of their informants, 
completed the DAS, Apathy Evaluation Scale (AES) and the Geriatric Depression 
Scale- Short form (GDS-15). Motor staging and independent living status were 
recorded. Results: Comparative group analyses revealed that PD patients were 
significantly more apathetic on self-rated Executive (p = .01) and Initiation (p = .03) 
dimensions than controls, where only Executive apathy was significantly higher in 
ratings of patients’ informants/carers compared to controls’ informants (p = .02). A 
third of patients were impaired on at least one apathy dimension. Additionally, 
patients with apathy tended to have more impaired activities of daily living, while 
none of the apathy dimensions related to motor disability. Conclusion: Our findings 
show the DAS is a valid and reliable multidimensional apathy tool for use in PD. PD 
is characterised by an Executive apathy profile as determined by informants/carers, 
although patients described both Executive and Initiation apathy. This indicates a lack 
of motivation for planning, organization and attention and lack of initiation of 
thoughts or behaviours. Further research is needed to determine the cognitive 
















Apathy is an important symptom for patients living with Parkinson’s disease (PD) and 
their carers. It is common in PD, affecting between 30% to 51% of patients (den Brok 
et al., 2015; Dujardin et al., 2007; Kirsch-Darrow et al., 2006; Pedersen et al., 2009) 
and is associated with decreased quality of life (Benito-León et al., 2012; Laatu et al., 
2013) and cognitive impairment (Dujardin et al., 2010; Pluck and Brown, 2002). It is 
also a symptom that affects carers, and is associated with increased distress and 
burden in caregivers (Leiknes et al., 2010; Leroi et al., 2012). 
 
Apathy is not a one-dimensional symptom, but is a syndrome (Marin, 1991) 
comprised of several dimensions, domains or subtypes; some differentiation between 
components of apathy in PD has been suggested (Kay et al., 2012) and with some 
scales used to measure numerous sub-factorial domains of apathy, such as the Lille 
Apathy Rating Scale (LARS) e.g. (Dujardin et al., 2007). The LARS measures four 
domains of apathy pertaining to action initiation (unproductive in day-to-day life and 
lessened initiative), intellectual curiosity (lack of novelty seeking, interest and 
motivation), emotion (emotional blunting of responses and diminished concern) and 
self-awareness (metacognition and awareness). Levy and Dubois (Levy, 2012; Levy 
and Dubois, 2006) proposed an emerging triad of neurobiological apathy subtypes, 
which associate with lack of motivation and goal-directed behaviours. These subtypes 
are Auto-activation apathy as a lack of activity or initiation of thought or action, 
Emotional-affective apathy which impacts processing of emotional information 
observable as emotional blunting or indifference and, finally, Cognitive apathy (or 
Cognitive inertia) as an inability to expand on plans, organise or manage goals 
associated with plans. A comprehensive review of multidimensional 
conceptualization of apathy and associated neuroimaging findings provided support 
for Levy and Dubois apathy subtyping in PD (Pagonabarraga et al., 2015). 
Specifically, it suggested the most common subtype impairments would be 
manifested as Cognitive apathy and Emotional-affective apathy, based on 
neurobiological pathways affected in PD. However, there has been no scale validated 
in PD that measures these subtypes directly.  
 
The Dimensional Apathy Scale (DAS: Radakovic and Abrahams, 2014) was 
specifically designed to measure dimensions of apathy known as Executive (planning, 
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attention and organization), Emotional (emotional neutrality/indifference) and 
Initiation (self-generated behaviours or cognition) apathy, which are akin to Levy and 
Dubois Cognitive, Emotional-affective and Auto-activation apathy subtypes, 
respectively. It is the only scale created based on Levy and Dubois’ triadic apathy 
subtypes. It has been validated in amyotrophic lateral sclerosis, quantifying a unique 
apathetic profile deficit of Initiation apathy and measured multidimensional apathy 
independent of motor disability (Radakovic et al., 2016), therefore making it suitable 
for use in PD patients. 
 
The aims of this preliminary study were to validate both the self-rated and 
informant/carer-rated DAS in a sample of PD patients and explore the profile of 
multidimensional apathy in PD patients. This study also aimed to determine the 
relationship of multidimensional apathy with other clinical variables, including motor 




Patients were recruited from a Movement Disorders Clinic, lead by RD, between 
February 2014 and September 2015. 54 probable idiopathic PD patients and their 54 
informants/carers were approached to participate. 5 patients were excluded due to pre-
existing medical problems, including previous brain injury and other significant 
illness, and 15 patients did not participate. 34 patients and 30 of their 
informants/carers (spouses, family members or close friends of patients) participated 
in the study. No PD patients had dementia. 34 matched age-gender-education healthy 
controls and 30 of their informants (spouses, family members or close friends of 
controls) from the University of Edinburgh Volunteer Panel were screened for pre-
existing medical problems and recruited to participate. 
 
Ethical approval was obtained from the National Health Service (NHS) South East 
Scotland Research Ethics Committee 02 and the School Philosophy, Psychology and 
Language Sciences (PPLS), University of Edinburgh Ethical Committee, in 






All participants (Patients and their informants/carers, controls and their informants) 
completed two apathy measures, for psychometric comparison (convergent validity), 
and one depression measure, to explore the relationship of multidimensional apathy 
with depression. Informants/carers completed the questionnaires about their 
observations of the patients and controls. 
 
Multidimensional apathy was assessed using the self and informant/carer versions of 
the DAS (Radakovic and Abrahams, 2014), which is composed of 3 subscales 
assessing Executive, Emotional and Initiation apathy subtypes. The minimum score 
for each subscale is 0 (least apathy) and the maximum 24 (most apathy). The scale 
was validated in an amyotrophic lateral sclerosis (Radakovic et al., 2016). Impairment 
on the DAS subscales was calculated on the basis of ≥2 SD above the mean of the 
control sample. The self and informant version of the AES (Marin et al., 1991) were 
used as a unidimensional measure of apathy, which produces one composite score, 
with the minimum score of 18 (least apathy) and maximum score of 72 (most apathy). 
The AES has been validated in PD (Santangelo et al., 2014) with suggested cutoffs of 
39 for the self-rated and 40 for the informant/carer-rated versions, which are based on 
≥2 SD above the mean of control sample in (Marin et al., 1991). 
 
Depression was measured by the self and informant versions of the Geriatric 
Depression Scale-Short form (GDS-15: Brown and Schinka; 2005, Yesavage and 
Sheikh, 1986) with the minimum score is 0 (not depressed) with the maximum being 
15 (most depressed). Clinical cutoff of >6 were used for presence of depressive 
symptoms (Wancata et al., 2006).  
 
Informants completed the Lawton Instrumental Activities of Daily Living (LIADL: 
Lawton and Brody, 1969) to assess functional independence. Total scores range from 
0 (low function, dependent) to 8 (high function, independent). Finally, PD patients 
were staged using the Hoehn and Yahr scale (HY) (Hoehn and Yahr, 1967). 
Clinician’s notes, observation and HY score were used to define on-off state, in 






SPSS 21.0 and R were used for statistical analysis. The Shapiro-Wilk test was used to 
test normality, which served as a basis for whether parametric and non-parametric 
statistics were used for subsequent analyses. Independent t-tests, Mann-Whitney U 
tests and Chi-square tests were used to compare demographics, symptom frequency 
and clinical variables (apathetic patients vs non apathetic patients). Psychometric 
properties of the DAS were determined using Holm corrected Pearson’s r for 
convergent validity and divergent validity. Cronbach’s Standardized alpha was also 
used to determine internal consistency reliability. 2 x 3 mixed design ANOVAs were 
used for Group (Patients/Informants vs Controls/Informants) and DAS subscale 




There were no significant differences between age, sex and years of education of PD 
patients and healthy controls (Table 1). Most informants/carers were spouses, for both 
patients and healthy controls. 76.5% of PD patients were taking dopaminergic 
medication. 
 
Table 1.  
 
Psychometrics of the DAS 
 
Table 2.  	
Table 2 shows that DAS subscales correlated positively with the AES, with the self-
rated Emotional and Initiation subscales correlating strongly and Executive 
correlating moderately with the AES, and not correlating significantly with the GDS-
15. The informant/carer-rated DAS subscales scores were positively correlated with 
the AES, with Executive and Initiation subscales correlating strongly and the 
Emotional correlating moderately. The Emotional subscale did not significantly 
correlate with the GDS-15. A positive correlation was observed between the AES and 
GDS-15, for both self (r(32) = .55, p < .001)  and informant/carer ratings (r(28) = .74, 




The Cronbach’s Standardized alpha value for the self-rated DAS was 0.84 and for the 
informant/carer-rated DAS was 0.92, which were good and excellent, respectively. 
With regards to DAS subscales, the Executive (self = 0.81, informant/carer = 0.90) 
and Initiation (self = 0.76, informant/carer = 0.90) subscales were good to excellent. 
The self-rated Emotional subscale was found to be questionable (0.56), while the 
informant/carer-rated version of the Emotional subscale was found to be more 
acceptable (0.71). 
 
Apathy and Depression  
 
Table 3.  
 
Table 3 shows patients’ and controls’ (self and informant/carer-rated) scores on 
apathy and depression measures. Apathy was significantly higher on the informant-
rated AES and on the self-rated DAS total in PD patients compared with healthy 
controls. Both informant and self-rated PD patient group depression scores differed 
significantly from those of controls.  
 
There was no significant correlation between the HY scale and either the DAS 
Executive, Emotional, Initiation or the total scores for either self or informant/carer-
rated versions. 
 




In Figure 1a, the Group (Patient vs Control) and self-rated DAS Subscale comparison 
showed a significant main effect for DAS subscale (F(2,132) = 46.05, p < .001), 
indicating there was a difference between DAS subscales. There was no significant 
interaction between DAS subscale and Group in self-rated scores (p = .10), but there 
was a significant main effect for Group (F(1,66) = 5.70, p = .02), where overall 
patients in self ratings were significantly more impaired than controls on the DAS 
subscales. Post hoc independent t-tests showed self-rated patients scoring higher than 
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controls on the Executive (t(66) = -2.58, p = .01) and Initiation (t(66) = -2.28, p = .03) 
subscales. 
 
In Figure 1b, the Group (Patients’ informants/carers vs Controls’ informants) and 
DAS Subscale comparison informant/carer ratings showed a significant main effect 
for DAS subscale (F(2,116) = 33.86, p < .001). There were no significant main effect 
for Group (p = .07) or significant Group and DAS Subscale interaction (p = .19). 
However, post hoc independent t-tests showed that informant/carer-rated patients 
scored significantly higher than informant-rated controls on the Executive subscale 
(t(58) = -2.34, p = .02). 
 
There was no significant difference between self-ratings and informant/carer-ratings 




On the self-rated DAS showed 38% (N = 13) of PD patients were impaired on at least 
one apathy subscale. Of these, eleven were impaired on just one subscale, of which 
seven were impaired only on the Executive, three only on the Initiation and one only 
on the Emotional subscale. One was found to be impaired on two subscales, the 
Executive with Initiation subscales, and one was globally impaired on all three 
subscales. In controls only two participants were impaired on the DAS, one on the 
Executive and one on the Initiation subscale. The frequency of abnormal apathy was 
significantly higher in patients than healthy controls (p = 0.001). No such difference 
was observed on the self AES between patients (N = 5 impaired) and controls (N = 2 
impaired). 
 
On the informant-rated DAS, 33% (N = 10) of patients were impaired on at least one 
subscale. Of these, four were impaired on only one subscale, three of which were 
impaired only on the Initiation and one on the Emotional subscale. Five were 
impaired on two subscales, of those three were impaired on Executive with Initiation 
and two on Executive with Emotional subscales. Global impairment on all three 
subscales was observed in one patient. The most common impairment on two 
subscales was that of Executive with Initiation apathy. In informants of controls only 
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three participants scored impaired on the DAS, with one on the Executive, one on the 
Emotional and one on all subscales. Once more, informant/carer ratings, the 
frequency of patients impaired on apathy subscales was significantly higher than 
controls (p = 0.03). No such difference was observed on the informant AES between 
patients (N = 5 impaired) and controls (N = 3 impaired). 
 
 
Clinical variable comparison 
 
Table 4.  
 
Table 4 shows a comparison of clinical variables based on informant/carer DAS 
ratings where PD patients were separated into two groups: impaired on one or more 
(≥1) subscales and unimpaired on any subscales of the DAS. The only significant 
difference was found on the instrumental activities of daily living measure (LIADL), 




Prevalence of apathy in these PD patients, as determined by the DAS, was 38% by 
self rating and 33% by informant/carer ratings. This is consistent with previously 
reported apathy prevalence rates (den Brok et al., 2015; Dujardin et al., 2007; Kirsch-
Darrow et al., 2006; Pedersen et al., 2009), demonstrating that the DAS is sensitive to 
apathy in PD. Furthermore the DAS was able to detected more patients than controls 
with apathy subtype impairments, unlike the AES where the number of patients and 
controls with apathy were found to be similar. Most importantly the DAS quantified 
subtype impairments in relation to the Levy and Dubois triadic subtyping. Overall the 
psychometric properties of the self-rated and informant/carer-rated DAS in PD 
patients were found to be positive, with good convergent validity. Emotional apathy 
(that relating to indifference and neutrality) was consistently not correlated with 





Specific apathy subtype impairments were observable in self-rated PD patients, where 
they scored significantly higher on both the Executive and Initiation apathy subscales 
compared to controls. The informant/carer-rated comparison showed only Executive 
apathy as higher in PD patient compared to controls’ informants’ ratings. Therefore, 
Executive apathy appears to be the most reliable subtype impairment in PD patients. 
Generally, executive dysfunction is well documented in PD and has been shown to 
have associations with apathy (Dirnberger and Jahanshahi, 2013). Specifically 
research has found that apathy, as measured by the AES, in PD patients was 
associated with impaired performance on letter fluency, the Stroop task, more 
preservative errors in set shifting, backward digit span, free recall and recognition 
memory (Pluck and Brown, 2002; Varanese et al., 2011). Furthermore, a study found 
that planning related executive functioning tasks specifically were strongly associated 
with apathy (Weintraub et al., 2005). The current findings demonstrated that 
Executive apathy was particularly affected, associated with a lack of motivation for 
planning, organization and attention (Radakovic and Abrahams, 2014), which relates 
well to the above mentioned cognitive and executive dysfunction associated with 
apathy in PD. Previous research (Dujardin et al., 2007, Dujardin et al., 2014) using 
the LARS found that in PD the most commonly affected apathy domains were action 
initiation (unproductive in day-to-day life and lessened initiative) and intellectual 
curiosity (lack of novelty seeking, interest and motivation), with one study (Drijgers 
et al., 2010) additionally endorsing the emotional dimension (emotional blunting of 
responses and diminished concern). However, the LARS was only found to be a 
robust unidimensional apathy measure (Radakovic et al., 2015) and its’ proposed 
dimensions do not map thematically on to Levy and Dubois subtyping unlike the 
DAS. Future research should use the DAS to assess apathy subtypes in PD and 
determine how they associate with cognitive and executive dysfunction. 
 
Initiation apathy was also found to be prominent when patients were compared to 
controls on the self-rated DAS. The DAS has previously shown that amyotrophic 
lateral sclerosis is characterised by Initiation apathy (Radakovic et al., 2016), whereas 
this study indicates that PD is characterised by a combination of Executive and, from 
only the self-rated perspective, Initiation apathy. It could be considered that the role 
of the informant in caring for the individual and, in doing so, motivating them 
throughout daily life and the disease course may impact on their perception of apathy 
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(i.e. through providing external cues to help the motivate towards an Initiation 
process). It has been observed that motivation through external cueing has been 
effective for certain apathy subtypes (Levy, 2012; Levy and Dubois, 2006), which 
could therefore make it more difficult for some informants/carers to observe and rate 
certain aspects of apathy, but research is needed to support this. However, when 
comparing patient and informant/carer ratings, there were no consistent discrepancies 
between scoring on any of the DAS subscales. This is indicative of preserved 
awareness of apathy in PD patients and also observation of apathy by their 
informant/carers.	
 
Emotional apathy was not found to differ between patients and controls, which is 
contrary to the predictions of previous research (Pagonabarraga et al., 2015). While 
there were cases of Emotional apathy in our sample, they seldom occurred in 
isolation, and were most often found in conjunction with another subtype impairment. 
This is likely due to the overlapping networks and involvement of dopamine in 
relation to goal-directed behaviour systems (Levy, 2012; Levy and Dubois, 2006). 
While dopamine depletion in the mesocorticolimbic system results in emotional 
under-reactivity (Pagonabarraga et al., 2015), akin to Emotional apathy, it has also 
been implicated in decision-making and strategy formation (Levy, 2012; Levy and 
Dubois, 2006), akin to Executive apathy. In PD, previous research has shown that 
early drug naïve patients display more apathy than those undergoing dopaminergic 
treatment (Zis et al., 2015) and a recent review provided evidence that behaviour 
syndromes such as apathy are hypodopaminergic, improving with use of dopamine 
agonists (Castrioto et al., 2016). However, no research has directly examined apathy 
subtype associations with this type of treatment in PD, which might help further 
elucidate the apathy-dopamine relationship. 
 
In relation to functional ability, a notable difference was observed with patients 
impaired on one or more subscales being found to have more difficulties with 
instrumental activities of daily living. Apathy has been previously associated with 
problems with activities of daily living in PD patients (Laatu et al., 2013) In our study 
PD patients were found to be most commonly impaired on two subscales, which were 
Executive and Initiation apathy. Motivation in relation to planning, organization and 
attention in combination with initiation of thoughts or behaviours are all important in 
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an individual’s ability to function independently. Of note, there appeared to be no 
significant relation between motor disability (HY stages) and apathy dimensions 
indicating that apathy may have an independent effect on daily life but more research 
is needed to explore this further. 
 
Due to the small sample size of patients (N = 34) and informants/carers (N = 30), 
Cronbach’s standardized alpha values should be interpreted with caution and restraint, 
in relation to internal consistency reliability. Additionally, a general point, this is a 
small sample study that provides the groundwork for further use of the DAS in PD to 
detect these specific apathy subtypes. Further large-scale, replication is needed to 
determine the apathy subtype profile in PD and how it relates to other clinical related 
variables throughout the disease process. With the availability of diagnostic criteria 
for apathy (Robert et al., 2009) and its application in relation to validating the AES in 
PD (Santangelo et al., 2014), there is further remit to explore the application of the 
DAS in relation to clinically observable apathy. 
 
Conclusions 
To conclude, through this study of multidimensional apathy in PD patients, the self-
rated and informant/carer-rated DAS was found to be a valid, reliable and effective 
instrument for measuring multidimensional apathy. PD seems to be characterised by 
Executive apathy (a lack of motivation for attention, planning and organization) and, 
to some extent, Initiation apathy (lack of motivation for self-generation of thoughts or 
actions), in relation to other disorders such as amyotrophic lateral sclerosis. Both the 
self-rated and informant/carer-rated DAS were not associated with motor disability in 
PD patients and there was no impaired awareness in relation to apathy subtypes. 
Further research should explore how apathy subtypes associate with other cognitive 
functioning, executive functioning and clinical variables, which will help further 
uncover the mechanisms of different apathy subtypes. 
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Table 1. Demographics for PD patients (N=34) and controls (N=34) 
 Patient Control Patient vs Control 
p-value 
Gender (M/F) 15/19 15/19 1.00 
Age (mean, SD) 68.2 (9.2) 66.1 (9.2) 0.36 
Years of Education (mean, SD) † 14.4 (4.8) 16.5 (3.0) 0.08 
HY Score (mean, SD) 2.3 (1.1)   
LIADL Score (mean, SD) ††  6.8 (1.2)   
Age of onset (mean, SD) years 68.2 (9.2)   
Disease duration (mean, SD) 
years 
4.4 (3.3)   
SD=standard deviation; LIADL=Lawton Instrumental Activities of Daily Living; HY=Hoehn & 
Yahr scale 
Significant difference highlighted in bold 
† N = 32 




Table 2. Patient self-rated and informant/carer-rated DAS subscale correlations 
compared to standardised apathy (AES) and depression (GDS15) measures  
Self (N=34) AES GDS-15 
DAS Executive subscale 0.57** 0.54* 
DAS Emotional subscale 0.59** 0.46 
DAS Initiation subscale 0.70*** 0.43 
DAS Total 0.80*** 0.61** 
Informant/Carer (N=30) AES GDS-15 
DAS Executive subscale 0.78*** 0.75*** 
DAS Emotional subscale 0.63** 0.45 
DAS Initiation subscale 0.79*** 0.73*** 
DAS Total 0.90*** 0.80*** 
DAS=Dimensional Apathy Scale; AES=Apathy Evaluation Scale; GDS-15=Geriatric Depression 
Scale- Short Form       p<.001***, p<.01**, p<.05* 




Table 3. Apathy and depression descriptive data for PD patients (N=34) and 
controls (N=34) 
 Patient Control Patient vs Control p-value 
DAS (mean, SD)    
Self-rated total 25.8 (8.7) 21.2 (7.0) 0.02 
Informant/Carer-rated total† 25.1 (12.8) 19.7 (9.5) 0.07 
AES Score (mean, SD)    
Self-rated 30.1 (6.9) 28.4 (5.5) 0.28 
Informant-rated† 31.4 (9.1) 27.2 (6.6) 0.045 
GDS-15 (mean, SD)    
Self-rated 3.5 (2.9) 1.6 (1.8) 0.002 
Informant-rated† 3.5 (3.9) 1.8 (2.1) 0.001 
SD=standard deviation; DAS=Dimensional Apathy Scale; AES=Apathy Evaluation Scale; GDS-
15=Geriatric depression scale- Short form 
Significant difference highlighted in bold 
† N= 30 	
Table 4. Clinical variable comparison of patients’ (informant/carer-rated) 
impaired on ≥1 DAS Subscales (N=10) to patients unimpaired on all subscales 
(N=20) 
 ≥1 Subscale 
Impairment 
Unimpaired p-value 
HY (Mean, SD) 1.5 (0.7) 2.4 (1.1) .59 
LIADL (Mean, SD) 6.1 (1.1) † 7.3 (1.1) †† .007 
Disease duration (Mean, SD) 4.2 (3.1) 4.7 (3.3) .58 
Age of Onset (Mean, SD) 64.7 (13.8) 70.2 (5.8) .35 
On-Off-No medication state (%)    
 On (N=13) 30.8% 69.2%  
 Off (N=11) 36.4% 63.6% .75 
 No Medication (N=6) 33.3% 66.7%  
LIADL=Lawton Instrumental Activities of Daily Living; HY=Hoehn & Yahr scale; SD=standard 
deviation 
Significant difference highlighted in bold 
† N= 9; †† N= 19 
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